Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.
Investors are currently deciding between Amgen Inc. (AMGN -0.79%) and Pfizer Inc. (PFE +0.88%) as potential 2027 stock purchases. Both companies are leaders in the healthcare sector but differ in their business models and market positions.
Amgen specializes in specialized biological medicines, particularly in oncology and rare diseases. It delivers its products to patients in about 100 countries through distributors such as McKesson Corp., Cencora Inc., and Cardinal Health Inc. These partners account for 77% of Amgen's revenue, making revenue concentration a significant risk factor for the company.
In the fiscal year ending December 31, 2025, Amgen reported revenue of approximately $36.7 billion, a 10% increase from the previous year. The company generated a net income of around $7.7 billion, resulting in a net margin of roughly 21%. This growth is driven by its innovative drug portfolio serving general medicine and oncology patients globally.
Amgen’s debt-to-equity ratio stands at approximately 6.3x, indicating a higher level of leverage. Its current ratio is about 1.1x, suggesting sufficient short-term assets to cover liabilities. Additionally, Amgen produced free cash flow of around $8.1 billion in 2025.
Pfizer, on the other hand, is a global pharmaceutical company operating in nearly 200 countries and territories. Pfizer specializes in vaccines, medicines, and treatments for a broad range of markets. It relies on a vast distribution network and pharmacy chains, contributing to its global presence. In 2025, Pfizer reported revenue of approximately $62.6 billion, a slight decline of 1.6% year-over-year.
The company generated a net income of roughly $7.8 billion, with a net margin of approximately 12.4%. Pfizer maintains a lower debt-to-equity ratio of about 0.8x, indicating a more conservative capital structure. Its current ratio is approximately 1.2x, reflecting strong liquidity. Lastly, Pfizer generated free cash flow of nearly $9.1 billion in 2025.
While both companies face challenges such as patent cliffs, regulatory shifts, and competition, Amgen is currently offering a higher revenue growth rate and has a more conservative capital structure. However, Pfizer appears to be a more cost-effective option based on its lower Forward P/E and P/S ratios. Amgen's potential for growth, including its ability to pursue acquisitions and price reductions, could make it a compelling long-term investment. Investors should carefully consider these factors in their decision-making process.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
